Glucagon-like peptide 1 (GLP-1) and eating

• Published in: Physiology & behavior Vol. 82; no. 1; pp. 17 - 19
• Main Authors: Gutzwiller, Jean-Pierre, Degen, Lukas, Heuss, Ludwig, Beglinger, Christoph
• Format: Journal Article
• Language: English
• Published: Cambridge Elsevier Inc 01.08.2004; New York, NY Elsevier
• Subjects: Animals; Antibodies - pharmacology; Appetite control; Biological and medical sciences; Digestive System; Eating - physiology; Feeding. Feeding behavior; Fundamental and applied biological sciences. Psychology; Glucagon - agonists; Glucagon - immunology; Glucagon - physiology; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Obesity; Peptide Fragments - agonists; Peptide Fragments - immunology; Peptide Fragments - physiology; Protein Precursors - agonists; Protein Precursors - immunology; Protein Precursors - physiology; Receptors, Glucagon - physiology; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Obesity; Glucagon-like peptide 1; Appetite control; Feeding behavior; Gastrointestinal hormone; Food intake; Nutrition disorder; Satiety; Review; Nutritional status; Ingestion; Glucagon like peptide 1
• ISSN: 0031-9384; 1873-507X
• DOI: 10.1016/j.physbeh.2004.04.019

New information regarding gastrointestinal mechanisms that participate in the control of food intake has extended our understanding of appetite control. Although each new signaling pathway discovered in the gut is a potential target for drug development in the treatment of obesity, the growing number of such signaling molecules indicates that a highly complex process controls food intake. The present summary focuses on the role of glucagon-like peptide 1 (GLP-1) in this regulatory process. The different biological effects of GLP-1 (glucose-lowering properties, inhibition of appetite and food intake) provide a powerful impetus for development of GLP-1-based new drugs.